Select Page

OCTOBER 2-4, 2018

Quebec City Convention Centre, Canada


MD, CEO Gynov / Indigo therapeutics – France

“PCOS management in 2018: inositol in the spotlight”


After his medical studies, Pierre-Yves Mousset worked for 15 years in communication and pharmaceutical marketing. He is the founder and CEO of Gynov and Indigo therapeutics, companies specializing in the development of food supplements, Special Medical Foods and medical devices for women’s health for the former, clinical nutrition and intestinal microbiota modulation for the latter. Based on the belief that certain food ingredients are likely to bring under-exploited health benefits, these companies are engaged in the development of products that meet the quality criteria of the pharmaceutical industry, both from an industrial point of view and from the scientific and medical requirements essential to health professionals.


Although representing more than half of humankind, women suffer from a lack of scientific and medical attention. Women experience unique health issues, from pregnancy and menopause to gynecological conditions. Extremely prevalent conditions are still today situations for which the medical need is not satisfied. Polycystic ovary syndrome (PCOS) is the most common endocrinopathy, affecting 5–20% of women of reproductive age worldwide. The condition is characterized by hyperandrogenism, ovulatory dysfunction and polycystic ovarian morphology with metabolic dysfunction characterized by insulin resistance and compensatory hyperinsulinaemia playing a key role in the pathogenesis, both in lean and obese women. PCOS increases the risk for infertility, type 2 diabetes mellitus, gestational diabetes and other pregnancy-related complications, venous thromboembolism, cardiovascular events and endometrial cancer. There are few medications that are approved for the most prevalent symptoms of PCOS, leading to the off-label use of medications, the most common of which being metformin. Research of other effective therapeutic options has included the utility of inositols, belonging to the polyols family. The rationale underlying their use relies on their activities as insulin mimetic agents and their salutary effects on metabolism and hyperandrogenism without side effects. Despite a significant number of clinical studies, some of which meeting the highest quality criteria, the medical community has shown little interest in these products, probably because of their non-drug status. While it is generally accepted that dietary measures are the cornerstone of care, certain natural food supplements should be eligible for medical support as long as they provide a sufficient level of evidence. However, this situation is in the process of changing with the inclusion of an ‘Inositol’ chapter in the ASRM/ESHRE 2018 Guidelines and with properly randomized controlled studies on large cohorts of PCOS women. 


The international rendezvous on health ingredients that will be held from October 2 to 4, 2018, at the Quebec City Convention Centre in Canada. Anchored in Quebec City’s reputation for excellence in food and health, BENEFIQ is a must-attend event sparking synergy among scientists and industry professionals from this rapidly evolving sector.
An initiative of the Institute of Nutrition and Functional Foods (INAF)


Share This